Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Treasury Shares (2023 - 2025)

Zenas BioPharma has reported Treasury Shares over the past 3 years, most recently at $599675.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $599675.0 for Q4 2025, up 2732.4% from a year ago — trailing twelve months through Dec 2025 was $599675.0 (up 2732.4% YoY), and the annual figure for FY2025 was $599675.0, up 2732.4%.
  • Treasury Shares for Q4 2025 was $599675.0 at Zenas BioPharma, up from $525350.0 in the prior quarter.
  • Over the last five years, Treasury Shares for ZBIO hit a ceiling of $599675.0 in Q4 2025 and a floor of $21172.0 in Q1 2024.
  • Median Treasury Shares over the past 3 years was $269150.0 (2023), compared with a mean of $284278.2.
  • Biggest five-year swings in Treasury Shares: dropped 22.16% in 2024 and later skyrocketed 2732.4% in 2025.
  • Zenas BioPharma's Treasury Shares stood at $27200.0 in 2023, then decreased by 22.16% to $21172.0 in 2024, then skyrocketed by 2732.4% to $599675.0 in 2025.
  • The last three reported values for Treasury Shares were $599675.0 (Q4 2025), $525350.0 (Q3 2025), and $511100.0 (Q2 2025) per Business Quant data.